Breaking News

Tweet TWEET

New Expert White Paper Recommends Framework for Action to Tackle Impact of ADHD on Individuals, Families and Society

  New Expert White Paper Recommends Framework for Action to Tackle Impact of
                  ADHD on Individuals, Families and Society

  PR Newswire

  BRUSSELS, April 23, 2013

BRUSSELS, April 23, 2013 /PRNewswire/ --

A new Expert White Paper,  ADHD: Making the Invisible Visible, was today
presented to policymakers and key stakeholders by a multidisciplinary group of
experts.

This Expert White Paper project was initiated, facilitated and funded by Shire
AG and supported by the European Brain Council (EBC) and GAMIAN-Europe (Global
Alliance of Mental Illness Advocacy Networks). Medical writing support was
provided by APCO Worldwide and Complete Medical Communications, and funded by
Shire AG.

The Expert White Paper, based on patient research and independent expert
opinion, demonstrates the substantial impact Attention Deficit/Hyperactivity
Disorder (ADHD) can have on an individual from childhood into adulthood, in
addition to the broader impact on families, welfare systems and national
budgets. ADHD: Making the Invisible Visible was launched by co-authors Dr
Susan Young, Dr Michael Fitzgerald, and Dr Maarten J Postma.

The findings of the Expert White Paper are supported by MEP, Nessa Childers,
co-chair of the European Parliament Interest Group on Mental Health : "Mental
health problems such as ADHD are unfortunately becoming far less of a priority
on the political agenda, particularly due to the current economic crisis
resulting in widespread cutbacks in resources. ADHD is one of the most
neglected and misunderstood psychiatric conditions in Europe. Very few people
affected by ADHD receive appropriate diagnosis and support, which leads to a
significant impact on quality of life and society. I am pleased that this
Expert White Paper lays out sensible and practical recommendations to help
ensure better recognition and management of ADHD by all relevant stakeholders
working in healthcare, schools, the criminal justice system and the
workplace."

ADHD affects 1 in 20 children and adolescents in Europe ^[ ^1 ^] and, in many
cases, persists into adulthood. ^[ ^2 ^] The Paper highlights that adolescents
with a history of childhood ADHD tend to experience greater peer rejection and
have fewer close friendships ^[ ^3 ^] and that children with ADHD are more
likely to be bullied than their peers. ^[ ^4 ^] Academic outcomes are also
highlighted as a key impact area for people with ADHD if not managed
effectively, and problems at school may evolve into difficulties finding and
maintaining stable employment. ^[ ^5 ^] ^- ^[ ^7 ^]

"This Expert White Paper provides clear evidence that ADHD can have a marked
impact on self-esteem, social functioning and academic outcomes," said Dr Mary
Baker, President of the European Brain Council . "It also shows that timely
and effective management can improve quality of life and, with appropriate
support, there is potential for people with ADHD to lead fulfilled and
successful lives. We want to give everyone with ADHD this opportunity."

The Paper also highlights the broader psychological impact of ADHD,
particularly on parents who may also be affected and can experience
depression, anxiety and stress. ^[ ^8 ^] ^, ^[ ^9 ^] ADHD can also have a
negative and pervasive impact, with wide-ranging associated costs in terms of
healthcare or other services and long-term consequences for multiple aspects
of life. ^[ ^10 ^]

The Expert White Paper sets out five clear, workable recommendations
(including specific goals and a list of suggested actions) to help tackle the
impact of ADHD on individuals, families and society:

1.Increase informed awareness of ADHD
2.Improve access to early and accurate diagnosis of ADHD, especially via the
    introduction of early identification and intervention programmes in
    different policy areas (i.e., education, mental health-related services,
    criminal justice services and the workplace)
3.Improve access to ADHD treatment and develop a multidisciplinary
    patient-centred approach to ADHD care and support
4.Involve and support patient organisations
5.Encourage a patient-centred research agenda on ADHD, through more
    quantitative and qualitative research and through more involvement of
    allied stakeholders in developing priorities for future research.

"This Expert White Paper not only confirms the impact of ADHD, but most
importantly presents solutions to address the societal impact, costs and
long-term outcomes for affected individuals," said Pedro Montellano, President
of GAMIAN-Europe . "These concrete, expert-informed recommendations provide
policy makers with a chance to improve the lives of those affected by ADHD and
reduce the cost on national welfare systems across Europe. By working together
we can make a real difference."

NOTES TO EDITORS:

About the Expert White Paper

' ADHD: Making the Invisible Visible ' , An Expert White Paper on ADHD: policy
solutions to address the societal impact, costs and long-term outcomes, in
support of affected individuals.

This Expert White Paper project was initiated, facilitated and funded by Shire
AG and supported by the European Brain Council (EBC) and GAMIAN-Europe (Global
Alliance of Mental Illness Advocacy Networks). Medical writing support was
provided by APCO Worldwide and Complete Medical Communications, and funded by
Shire AG.

The Paper was developed on the basis of a European Expert Roundtable on ADHD,
with the participation of clinicians, patient advocacy groups and
representatives from the education and criminal justice systems. The
Roundtable addressed specific issues and challenges around the management of
ADHD and provided a forum for the discussion of policy recommendations. The
three co-authors, Dr Susan Young, Professor Michael Fitzgerald and Professor
Maarten J Postma, formulated the outcomes of the Roundtable into the White
Paper, which reflects their views based on their clinical and scientific
experiences.

About The European Brain Council (EBC;  http://www.europeanbraincouncil.org )

The EBC is a coordinating council formed by European organisations in
neurology, neurosurgery, psychiatry, basic brain research (neuroscience), as
well as patient organisations and industry. Itrepresents a vast network of
patients, doctors and scientists, and these stakeholders along with its
industrial partners make itsuited to work in close partnership with the EU
Commission, the European Parliament and the World Health Organization (WHO),
as well as other decision-making bodies. The EBC was officially founded on 22
March 2002 in Brussels, and has offices in Brussels and Florence.

About GAMIAN-Europe (Global Alliance of Mental Illness Advocacy Networks; 
http://www.gamian.eu ).

GAMIAN-Europe was established in 1998 as a representative coalition of patient
organisations. Putting the patient at the centre of all issues of the EU
healthcare debate, the organisation aims to bring together and support the
development and policy influencing capacity of local, regional and national
organisations active in the field of mental health. GAMIAN-Europe currently
brings together some 50 organisations (local, regional and national) from20
European countries.

About Shire AG

Shire AG is a wholly-owned subsidiary of Shire plc.

Shire enables people with life-altering conditions to lead better lives.
Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of:

  *Behavioral Health and Gastro Intestinal conditions
  *Rare Diseases
  *Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.

http://www.shire.com

Co-authors and Contributors

    Name                  Title                             Organisation

    Co-authors

    Susan Young           Clinical Senior Lecturer in       King's College London,
                          Forensic Clinical Psychology      Institute of Psychiatry, UK

    Michael Fitzgerald    Henry Marsh Professor of          Trinity College,
                          Child and Adolescent Psychiatry   Dublin, Ireland

    Maarten J Postma      Professor in Pharmacoeconomics    University of Groningen,
                                                            the Netherlands


    Contributors

    Phil Anderton         Management Consultant and         Justice in Mind Ltd
                          Director


    Kate Carr-Fanning     Vice Chairperson                  Hyperactivity Attention Deficit
                                                            Disorder (HADD), Ireland
                          PhD candidate                     School of Education, Trinity
                                                            College, Dublin, Ireland

    Goof Buijs            Senior Consultant and             School for Health Europe (SHE)
                          Programme Manager                 Dutch Institute for Healthcare
                                                            Improvement (CBO), Utrecht,
                                                            the Netherlands

    Stephanie Clark       Core group                        Aandacht Adult ADHD Support
                                                            Groups, Belgium

    Dolores Gauci         Immediate Past President          GAMIAN-Europe (Global Alliance
                                                            of Mental Illness Advocacy
                                                            Networks)

    Fulgencio Madrid      President                         Spanish Federation of ADHD
    Conesa                                                  Supporting Associations
                                                            (FEAADAH)

    Myriam Menter         Chief Executive Officer           ADHS Deutschland, Germany


    Joanne Norris         President and Education Chair     ADHD-ASC-LD Family Resources,
                                                            Belgium

    David Nutt            Vice-President                    European Brain Council (EBC)


    Gil Zalsman           Chair of Child and Adolescent     European Psychiatric
                          Psychiatry                        Association (EPA), France

Medical writing support was provided by APCO Worldwide and Complete Medical
Communications, and funded by Shire AG

References

1.Polanczyk G, et al. The worldwide prevalence of ADHD: a systematic review
    and metaregression analysis. Am J Psychiatry 2007;164:942-948.
2.Lara C, et al. Childhood predictors of adult
    attention-deficit/hyperactivity disorder: results from the World Health
    Organization World Mental Health Survey Initiative. Biol Psychiatry
    2009;65:46-54.
3.Bagwell CL, et al. Attention-deficit hyperactivity disorder and problems
    in peer relations: predictions from childhood to adolescence. J Am Acad
    Child Adolesc Psychiatry 2001;40:1285-1292.
4.Holmberg K, Hjern A. Bullying and attention-deficit hyperactivity disorder
    in 10 year olds in a Swedish community. Dev Med Child Neurol
    2008;50:134-138.
5.Biederman J, et al. Functional impairments in adults with self-reports of
    diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin
    Psychiatry 2006;67:524-540.
6.Barkley RA, et al. Young adult outcome of hyperactive children: adaptive
    functioning in major life activities. J Am Acad Child Adolesc Psychiatry
    2006;45:192-202.
7.Knapp M, et al. Economic outcomes in adulthood and their associations with
    antisocial conduct, attention deficit and anxiety problems in childhood. J
    Ment Health Policy Econ 2011;14:137-147.
8.Cussen A, et al. Relationship between symptoms of
    attention-deficit/hyperactivity disorder and family functioning: a
    community-based study. Eur J Pediatr 2012;171:271-280.
9.Pimentel MJ, et al. Mothers of children with attention
    deficit/hyperactivity disorder: relationship among parenting stress,
    parental practices and child behaviour. Atten Defic Hyperact Disord
    2011;3:61-68.
10.Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of
    long-term outcomes in attention deficit hyperactivity disorder: effects of
    treatment and non-treatment. BMC Med. 2012;10(1):99.

For further information please contact:

Just:: Health PR Rachel Bonny +44-20-8877-8426 rachel@justhealthpr.com

Ali Spink, +44-7980-924-298 ali@justhealthpr.com

European Brain Council Evelyn Sipido +39-055-43-62-098 evelyn.sipido@unifi.it

GAMIAN-Europe Paul Arteel +32-494-52-79-80 executive.director@gamian.eu